Total Funding
7
Total FundingDebt Financing raised
Growth Score
pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
656083
Stocosil is a pharmaceutical company delivering next generation products that treat the double-threat of hypertension and high cholesterol.
Osmond D'Cruz: Senior Director of Drug SafetyPast Role: Igdrasol Therapeutics, Held Positions
Chulho Park: Chief Business OfficerPast Role: Foundation for Applied Molecular Evolution, Held Positions
About the Company
Stocosil is a pharmaceutical company delivering next generation products that treat the double-threat of hypertension and high cholesterol.
Stocosil strikes at the heart of cardiovascular disease with their lead drug product, Kubiqo —a dual-drug pill that simultaneously treats hypertension and high cholesterol, reducing risk by a dramatic 45%.
Kubiqo is a fixed dose combination of olmesartan medoxomil and rosuvastatin calcium which currently does not exist in the United States.
In addition to Kubiqo, Stocosil has a strong pipeline of products that will tap into a large global market and multi-billion dollar revenue potential.
Stocosil boasts an impressive management team possessing significant experience in drug development.
